Efficacy and safety of dupilumab in pediatric patients with moderate to severe atopic dermatitis: a real-world study View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2022-08-21

AUTHORS

Dan-Yang Yang, Li Li, Tao Lu, Wen-Wen Jing, Xin Liu, Xiao-Li Li

ABSTRACT

Dupilumab is the first human monoclonal antibody that treats atopic dermatitis (AD) by blocking interleukin 4 (IL-4) and interleukin 13 (IL-13), which can suppress the Th2 inflammatory reaction. Effective treatments for pediatric AD patients are limited; therefore, we aimed to assess the efficacy and safety of dupilumab in pediatric AD patients. Fifteen pediatric patients diagnosed with moderate to severe AD and treated with dupilumab were enrolled in this study. SPSS was used to analyze data and obtain the average values of Eczema Area and Severity Index (EASI), SCORing AD (SCORAD), and Children’s Dermatology Life Quality Index (CDLQI). GRAPHPAD was used to analyze and plot the statistics. The average EASI values were 19.23 ± 3.03 and 1.69 ± 0.54 at baseline and at following up for 6 months after standardized treatment protocol, respectively. The average SCORAD values were 43.27 ± 4.63 and 6.13 ± 1.41 at baseline and at following up for 6 months after standardized treatment protocol, respectively. The average CDLQI value at baseline was 13.53 ± 2.88 and following up for 6 months after standardized treatment protocol was 1.60 ± 0.63. The most frequent adverse event was conjunctivitis. No serious adverse events occurred during the treatment period. Dupilumab could reduce symptoms and improve pruritus in pediatric AD patients, and the frequent adverse events were reversible. It has a definite therapeutic effect on AD; nevertheless, further studies should be conducted to obtain information on its the long-term efficacy and safety. More... »

PAGES

1-6

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00403-022-02380-w

DOI

http://dx.doi.org/10.1007/s00403-022-02380-w

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1150387897

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35989340


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Dermatology Department, Second Affiliated Hospital, Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, China", 
          "id": "http://www.grid.ac/institutes/grid.43169.39", 
          "name": [
            "Dermatology Department, Second Affiliated Hospital, Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yang", 
        "givenName": "Dan-Yang", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Dermatology Department, Second Affiliated Hospital, Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, China", 
          "id": "http://www.grid.ac/institutes/grid.43169.39", 
          "name": [
            "Dermatology Department, Second Affiliated Hospital, Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "Li", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Dermatology Department, Second Affiliated Hospital, Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, China", 
          "id": "http://www.grid.ac/institutes/grid.43169.39", 
          "name": [
            "Dermatology Department, Second Affiliated Hospital, Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lu", 
        "givenName": "Tao", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Dermatology Department, Second Affiliated Hospital, Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, China", 
          "id": "http://www.grid.ac/institutes/grid.43169.39", 
          "name": [
            "Dermatology Department, Second Affiliated Hospital, Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jing", 
        "givenName": "Wen-Wen", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Dermatology Department, Second Affiliated Hospital, Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, China", 
          "id": "http://www.grid.ac/institutes/grid.43169.39", 
          "name": [
            "Dermatology Department, Second Affiliated Hospital, Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Liu", 
        "givenName": "Xin", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Dermatology Department, Second Affiliated Hospital, Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, China", 
          "id": "http://www.grid.ac/institutes/grid.43169.39", 
          "name": [
            "Dermatology Department, Second Affiliated Hospital, Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "Xiao-Li", 
        "id": "sg:person.01236046127.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236046127.12"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s13555-021-00505-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1136371862", 
          "https://doi.org/10.1007/s13555-021-00505-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13555-021-00543-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1138399871", 
          "https://doi.org/10.1007/s13555-021-00543-7"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-08-21", 
    "datePublishedReg": "2022-08-21", 
    "description": "Dupilumab is the first human monoclonal antibody that treats atopic dermatitis (AD) by blocking interleukin 4 (IL-4) and interleukin 13 (IL-13), which can suppress the Th2 inflammatory reaction. Effective treatments for pediatric AD patients are limited; therefore, we aimed to assess the efficacy and safety of dupilumab in pediatric AD patients. Fifteen pediatric patients diagnosed with moderate to severe AD and treated with dupilumab were enrolled in this study. SPSS was used to analyze data and obtain the average values of Eczema Area and Severity Index (EASI), SCORing AD (SCORAD), and Children\u2019s Dermatology Life Quality Index (CDLQI). GRAPHPAD was used to analyze and plot the statistics. The average EASI values were 19.23\u2009\u00b1\u20093.03 and 1.69\u2009\u00b1\u20090.54 at baseline and at following up for 6\u00a0months after standardized treatment protocol, respectively. The average SCORAD values were 43.27\u2009\u00b1\u20094.63 and 6.13\u2009\u00b1\u20091.41 at baseline and at following up for 6\u00a0months after standardized treatment protocol, respectively. The average CDLQI value at baseline was 13.53\u2009\u00b1\u20092.88 and following up for 6\u00a0months after standardized treatment protocol was 1.60\u2009\u00b1\u20090.63. The most frequent adverse event was conjunctivitis. No serious adverse events occurred during the treatment period. Dupilumab could reduce symptoms and improve pruritus in pediatric AD patients, and the frequent adverse events were reversible. It has a definite therapeutic effect on AD; nevertheless, further studies should be conducted to obtain information on its the long-term efficacy and safety.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00403-022-02380-w", 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.4926794", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1054393", 
        "issn": [
          "0340-3696", 
          "1432-069X"
        ], 
        "name": "Archives of Dermatological Research", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }
    ], 
    "keywords": [
      "pediatric AD patients", 
      "standardized treatment protocol", 
      "Children's Dermatology Life Quality Index", 
      "Dermatology Life Quality Index", 
      "severe atopic dermatitis", 
      "frequent adverse events", 
      "atopic dermatitis", 
      "adverse events", 
      "AD patients", 
      "treatment protocol", 
      "pediatric patients", 
      "first human monoclonal antibody", 
      "definite therapeutic effect", 
      "serious adverse events", 
      "long-term efficacy", 
      "Life Quality Index", 
      "human monoclonal antibody", 
      "real-world study", 
      "Eczema Area", 
      "SCORAD values", 
      "treatment period", 
      "inflammatory reaction", 
      "therapeutic effect", 
      "interleukin-13", 
      "interleukin-4", 
      "effective treatment", 
      "patients", 
      "dupilumab", 
      "monoclonal antibodies", 
      "Severity Index", 
      "baseline", 
      "months", 
      "Further studies", 
      "efficacy", 
      "dermatitis", 
      "safety", 
      "pruritus", 
      "conjunctivitis", 
      "symptoms", 
      "Quality Index", 
      "antibodies", 
      "study", 
      "protocol", 
      "index", 
      "treatment", 
      "GraphPad", 
      "events", 
      "SPSS", 
      "period", 
      "effect", 
      "values", 
      "data", 
      "area", 
      "statistics", 
      "information", 
      "reaction", 
      "average value"
    ], 
    "name": "Efficacy and safety of dupilumab in pediatric patients with moderate to severe atopic dermatitis: a real-world study", 
    "pagination": "1-6", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1150387897"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00403-022-02380-w"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35989340"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00403-022-02380-w", 
      "https://app.dimensions.ai/details/publication/pub.1150387897"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T21:09", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_952.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00403-022-02380-w"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00403-022-02380-w'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00403-022-02380-w'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00403-022-02380-w'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00403-022-02380-w'


 

This table displays all metadata directly associated to this object as RDF triples.

152 TRIPLES      21 PREDICATES      82 URIs      72 LITERALS      5 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00403-022-02380-w schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Nf2fe414d9db14d808abacbfa179e637e
4 schema:citation sg:pub.10.1007/s13555-021-00505-z
5 sg:pub.10.1007/s13555-021-00543-7
6 schema:datePublished 2022-08-21
7 schema:datePublishedReg 2022-08-21
8 schema:description Dupilumab is the first human monoclonal antibody that treats atopic dermatitis (AD) by blocking interleukin 4 (IL-4) and interleukin 13 (IL-13), which can suppress the Th2 inflammatory reaction. Effective treatments for pediatric AD patients are limited; therefore, we aimed to assess the efficacy and safety of dupilumab in pediatric AD patients. Fifteen pediatric patients diagnosed with moderate to severe AD and treated with dupilumab were enrolled in this study. SPSS was used to analyze data and obtain the average values of Eczema Area and Severity Index (EASI), SCORing AD (SCORAD), and Children’s Dermatology Life Quality Index (CDLQI). GRAPHPAD was used to analyze and plot the statistics. The average EASI values were 19.23 ± 3.03 and 1.69 ± 0.54 at baseline and at following up for 6 months after standardized treatment protocol, respectively. The average SCORAD values were 43.27 ± 4.63 and 6.13 ± 1.41 at baseline and at following up for 6 months after standardized treatment protocol, respectively. The average CDLQI value at baseline was 13.53 ± 2.88 and following up for 6 months after standardized treatment protocol was 1.60 ± 0.63. The most frequent adverse event was conjunctivitis. No serious adverse events occurred during the treatment period. Dupilumab could reduce symptoms and improve pruritus in pediatric AD patients, and the frequent adverse events were reversible. It has a definite therapeutic effect on AD; nevertheless, further studies should be conducted to obtain information on its the long-term efficacy and safety.
9 schema:genre article
10 schema:isAccessibleForFree false
11 schema:isPartOf sg:journal.1054393
12 schema:keywords AD patients
13 Children's Dermatology Life Quality Index
14 Dermatology Life Quality Index
15 Eczema Area
16 Further studies
17 GraphPad
18 Life Quality Index
19 Quality Index
20 SCORAD values
21 SPSS
22 Severity Index
23 adverse events
24 antibodies
25 area
26 atopic dermatitis
27 average value
28 baseline
29 conjunctivitis
30 data
31 definite therapeutic effect
32 dermatitis
33 dupilumab
34 effect
35 effective treatment
36 efficacy
37 events
38 first human monoclonal antibody
39 frequent adverse events
40 human monoclonal antibody
41 index
42 inflammatory reaction
43 information
44 interleukin-13
45 interleukin-4
46 long-term efficacy
47 monoclonal antibodies
48 months
49 patients
50 pediatric AD patients
51 pediatric patients
52 period
53 protocol
54 pruritus
55 reaction
56 real-world study
57 safety
58 serious adverse events
59 severe atopic dermatitis
60 standardized treatment protocol
61 statistics
62 study
63 symptoms
64 therapeutic effect
65 treatment
66 treatment period
67 treatment protocol
68 values
69 schema:name Efficacy and safety of dupilumab in pediatric patients with moderate to severe atopic dermatitis: a real-world study
70 schema:pagination 1-6
71 schema:productId N799d4d43ea9d4c0b84b6e627cfe8629f
72 Nafd24efc123e4155b077b5917878d382
73 Nc50bade000ec40b485a3ef792127fb1b
74 schema:sameAs https://app.dimensions.ai/details/publication/pub.1150387897
75 https://doi.org/10.1007/s00403-022-02380-w
76 schema:sdDatePublished 2022-11-24T21:09
77 schema:sdLicense https://scigraph.springernature.com/explorer/license/
78 schema:sdPublisher N11fe86e77d8045dfaf6742a6af8245ce
79 schema:url https://doi.org/10.1007/s00403-022-02380-w
80 sgo:license sg:explorer/license/
81 sgo:sdDataset articles
82 rdf:type schema:ScholarlyArticle
83 N11fe86e77d8045dfaf6742a6af8245ce schema:name Springer Nature - SN SciGraph project
84 rdf:type schema:Organization
85 N13393b78684542a0a4fd296529fe92f2 rdf:first sg:person.01236046127.12
86 rdf:rest rdf:nil
87 N1a6d1170fc6a4fa192de995d18614aba rdf:first Nf2e17c27f32d4721a220e24341557fcd
88 rdf:rest Nb917476e72494580bcae6cf606d1fd41
89 N2d85616cc3534f03846ed926f0619d4d rdf:first N55b9b1faf52f44cebc20b9d884c2edeb
90 rdf:rest Nb3abbd696c334871be3501ad4a6cb5db
91 N45e9678a1b0a4c9eb4fb7cc56a3bb3c4 schema:affiliation grid-institutes:grid.43169.39
92 schema:familyName Lu
93 schema:givenName Tao
94 rdf:type schema:Person
95 N55b9b1faf52f44cebc20b9d884c2edeb schema:affiliation grid-institutes:grid.43169.39
96 schema:familyName Li
97 schema:givenName Li
98 rdf:type schema:Person
99 N799d4d43ea9d4c0b84b6e627cfe8629f schema:name dimensions_id
100 schema:value pub.1150387897
101 rdf:type schema:PropertyValue
102 Na11861eeaa5d4873a4a3a3ee4e854715 schema:affiliation grid-institutes:grid.43169.39
103 schema:familyName Yang
104 schema:givenName Dan-Yang
105 rdf:type schema:Person
106 Nafd24efc123e4155b077b5917878d382 schema:name doi
107 schema:value 10.1007/s00403-022-02380-w
108 rdf:type schema:PropertyValue
109 Nb3abbd696c334871be3501ad4a6cb5db rdf:first N45e9678a1b0a4c9eb4fb7cc56a3bb3c4
110 rdf:rest N1a6d1170fc6a4fa192de995d18614aba
111 Nb917476e72494580bcae6cf606d1fd41 rdf:first Nfe0a57c460c54c4395ce24e5eae7eb56
112 rdf:rest N13393b78684542a0a4fd296529fe92f2
113 Nc50bade000ec40b485a3ef792127fb1b schema:name pubmed_id
114 schema:value 35989340
115 rdf:type schema:PropertyValue
116 Nf2e17c27f32d4721a220e24341557fcd schema:affiliation grid-institutes:grid.43169.39
117 schema:familyName Jing
118 schema:givenName Wen-Wen
119 rdf:type schema:Person
120 Nf2fe414d9db14d808abacbfa179e637e rdf:first Na11861eeaa5d4873a4a3a3ee4e854715
121 rdf:rest N2d85616cc3534f03846ed926f0619d4d
122 Nfe0a57c460c54c4395ce24e5eae7eb56 schema:affiliation grid-institutes:grid.43169.39
123 schema:familyName Liu
124 schema:givenName Xin
125 rdf:type schema:Person
126 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
127 schema:name Medical and Health Sciences
128 rdf:type schema:DefinedTerm
129 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
130 schema:name Clinical Sciences
131 rdf:type schema:DefinedTerm
132 sg:grant.4926794 http://pending.schema.org/fundedItem sg:pub.10.1007/s00403-022-02380-w
133 rdf:type schema:MonetaryGrant
134 sg:journal.1054393 schema:issn 0340-3696
135 1432-069X
136 schema:name Archives of Dermatological Research
137 schema:publisher Springer Nature
138 rdf:type schema:Periodical
139 sg:person.01236046127.12 schema:affiliation grid-institutes:grid.43169.39
140 schema:familyName Li
141 schema:givenName Xiao-Li
142 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236046127.12
143 rdf:type schema:Person
144 sg:pub.10.1007/s13555-021-00505-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1136371862
145 https://doi.org/10.1007/s13555-021-00505-z
146 rdf:type schema:CreativeWork
147 sg:pub.10.1007/s13555-021-00543-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1138399871
148 https://doi.org/10.1007/s13555-021-00543-7
149 rdf:type schema:CreativeWork
150 grid-institutes:grid.43169.39 schema:alternateName Dermatology Department, Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, Shaanxi, China
151 schema:name Dermatology Department, Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, Shaanxi, China
152 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...